| Indication | Schizophrenia |
| Status | ‒ US Launched in November 2016 by Par Pharmaceutical. ‒ Canada Launched by a commercialization partner of Handa. |
| Product Advantages | ‒ First- to File, 180-day market exclusivity right in the USA. ‒ Final approval for 50 mg, 150 mg, 200 mg, 300 mg, and 400 mg. |
| Market Size | Handa has received profit sharing of more than $20 million in the USA and more than $3.5 million in Canada. |
?
R&D
Quetiapine XR
